VIEWPOINTS

Establishing Safe Treatment: Dr. Robert Rifikin from Rocky Mountain Cancer Centers in Conversation with PharmaShots

Shots: There is an average lifetime risk of getting multiple myeloma of about 1 in 103 men and 1 in 131 women in the United States Treatment of multiple myeloma using fourth-line therapy like teclistamab can induce issues like cytokine release syndrome (CRS) and neurotoxicity Today, at PharmaShots we have Dr. Robert Rifikin from Rocky…

August 5, 2024

Redefining Care: Gunjan Sharma from The US Oncology Network in Conversation with PharmaShots

Shots: Megestrol, an appetite stimulator is listed as an inappropriate medication based on the American Geriatrics Society (AGS) Beers Criteria and is considered a high-risk medication for elderly people by the Pharmacy Quality Alliance In a study by the US Oncology Network, the use of megestrol was reviewed and weight gain benefits was evaluated in…

July 31, 2024

Enhancing Capabilities: Tahi Ahmadi from Genmab in a Riveting Dialogue Exchange with PharmaShots

Shots: Recently, Genmab acquired ProfoundBio in a strategic move to strengthen its position in the ADC space. With this acquisition, Genmab gets ProfoundBio’s novel ADC technology platforms Today, at PharmaShots, we have Tahi Ahmadi, EVP and Chief Medical Officer at Genmab, sharing insights from the recent acquisition of ProfoundBio by Genmab With this acquisition, Genmab…

July 29, 2024

Expanding ADC Therapy: Jane Chung from Sutro Biopharma in an Engaging Conversation with PharmaShots

Shots: Luvelta, an antibody-drug conjugate by Sutro Biopharma is designed to target FRα, expressed in ovarian cancer, developed and manufactured using the company’s proprietary cell-free technology, XpressCF Today, at PharmaShots, we have Jane Chung, President and CEO at Sutro Biopharma, shedding on the ongoing REFRαME-O1 study evaluating luvelta Sutro is now enrolling patients for the…

July 24, 2024

Pipeline Overview: Paul A. Frohna from Endeavor BioMedicines in Conversation with PharmaShots

Shots: Paul A. Frohna, CMO at Endeavor BioMedicines, shed light on two lead assets of the company ENV-101 for Idiopathic Pulmonary Fibrosis and ENV-501 for HER 3 positive solid tumors. Paul shares insights from the P-IIa results of ENV-101 and talks about the WHISTLE-PF P-II study designed to confirm the efficacy of ENV-101. While shedding…

July 22, 2024

Inherited Retinal Disease Management: Brian Strem from Kiora Pharmaceuticals in a Stimulating Dialogue Exchange with PharmaShots

Shots: Recently, Kiora Pharmaceuticals received an upfront payment of $16M after inking the partnership agreement with Théa Open Innovation to develop and commercialize KIO-301 and is eligible to receive up to $285M KIO-301 belongs to a new-generation drug called molecular switches that offer a path around damaged receptors rather than looking to repair gene mutation …

July 15, 2024

Off the Shelf Platform: Efrat Kaduri from Pluri Inc. In a Riveting Conversation with PharmaShots

Shots: Recently, Pluri launched its placental allogenic MAIT cell platform for immunotherapy treatment of solid tumors. Mucosal Associated Invariant T (MAIT) cells offer better advantages as compared to conventional T cells Today, we have with us Efrat Kaduri shedding light on the potential of placental MAIT cells in treating solid tumors While highlighting the intellectual…

July 10, 2024

Redefining Technology: Xochitl Javier from Thermo Fisher Scientific in Conversation with PharmaShots

Shots: Raman Analyzers are widely used in the biopharma industry to analyze different substances. Based on the principles of Raman Spectroscopy, Raman Analyzers provide information about their chemical composition and structure when interacting with laser Today, at PharmaShots, we have Xochitl Javier, Director, Product Management & Marketing, Thermo Fisher Scientific, shedding light on the TruScan…

July 8, 2024

AstraZeneca at ATS’24: Andrew Menzies-Gow from AstraZeneca in a Stimulating Conversation with PharmaShots

Shots: AstraZeneca presented 59 abstracts, including 12 late-breaking posters at the American Thoracic Society, focussing on the unmet needs in COPD, EGPA, and other chronic respiratory diseases Today, at PharmaShots, we have Andrew Menzies-Gow, sharing insights from the MANDARA study that evaluated Fasenra (benralizumab) for EGPA, a rare debilitating condition Andrew stresses reducing the use…

July 3, 2024

Drug Pricing & Rebate Management: Jesse Mendelsohn from Model N in Dialogue Exchange with PharmaShots

Shots: Drug pricing reforms from the IRA continue to impact pharmaceutical companies. The rebates ensued from the IRA guidelines are heavily affecting the revenues of biopharma companies Today, at PharmaShots we have Jesse Mendelsohn, Sr. Vice President at Model N shedding light on the company’s recently launched solution called Medicare Part D inflation rebate-per-unit With…

July 1, 2024